

Public Policy Committee Charter

1. *Purpose.* The Public Policy Committee of the Board of Directors shall assist the Board in fulfilling its oversight responsibility with respect to:
 - public policy, regulatory (including regulation by the Federal Food and Drug Administration (FDA), as well as other domestic, foreign and international regulatory bodies) and government affairs; and
 - healthcare and other compliance issues (recognizing that other Board committees assist the Board of Directors in reviewing certain areas of legal and regulatory compliance).
2. *Organization.* All members of the Public Policy Committee must satisfy the independence requirements of the New York Stock Exchange, as such requirements are interpreted by the Board in its business judgment. Abbott's Board shall appoint, and may remove, members of the Public Policy Committee and the Committee's Chairman, acting on the recommendation of Abbott's Nominations and Governance Committee.
3. *Authority and Responsibilities.* The Public Policy Committee may, to the extent it deems necessary or appropriate, conduct or authorize investigations into any matter within the scope of its authority and may retain legal counsel, consultants and others to assist it in the conduct of its responsibilities, including investigations. The Public Policy Committee shall receive appropriate funding, as determined by the Public Policy Committee, from Abbott for payment of (a) compensation to any special legal, accounting or other consultants employed by the Public Policy Committee and (b) ordinary administrative expenses of the Public Policy Committee that are necessary or appropriate in carrying out its duties. The Public Policy Committee may consult with management and may delegate any of its responsibilities and duties to one or more members of the Public Policy Committee.

The Public Policy Committee shall meet at least four times a year and report to the Board on a regular basis; any additional meetings may be scheduled as the Public Policy Committee determines are necessary and appropriate.

The Public Policy Committee shall:

- Review and evaluate Abbott's policies and practices with respect to maintaining legal, regulatory and healthcare compliance (recognizing that other Board committees assist the Board of Directors in reviewing certain areas of legal and regulatory compliance), and review them with the Board as appropriate.
- Review and discuss with management regulatory and healthcare compliance matters. In particular, the Chief Ethics and Compliance Officer shall report to the Public Policy Committee at least three (3) times a year regarding regulatory and healthcare compliance matters, and the state of regulatory compliance and issues with respect thereto; any additional reports or discussions may be scheduled as the Public Policy Committee determines are necessary and appropriate.

- Review annually Abbott's compliance program with respect to legal and regulatory requirements, including FDA regulations, and receive a report from the corporate officer responsible for quality assurance as needed, but at least two (2) times a year, regarding any FDA warning letters and Abbott's responses, as well as any upcoming compliance initiatives.
 - Review and evaluate Abbott's policies and practices with respect to social responsibility, and review them with the Board as appropriate.
 - Review social, political, economic and environmental trends and public policy issues that affect or could affect Abbott's business activities, performance, and public image, and review them with the Board as appropriate.
 - Review and make recommendations to the Board regarding shareholder proposals submitted for inclusion in Abbott's proxy materials that relate to public policy or social responsibility issues.
4. *Annual Performance Review.* The Public Policy Committee shall review and assess the adequacy of its charter annually and recommend any proposed changes to the Board for approval. The Public Policy Committee shall annually evaluate its own performance.